| Literature DB >> 32967005 |
César Muñoz-Fontela1,2, William E Dowling3, Simon G P Funnell4, Pierre-S Gsell5, A Ximena Riveros-Balta5, Randy A Albrecht6, Hanne Andersen7, Ralph S Baric8, Miles W Carroll4, Marco Cavaleri9, Chuan Qin10, Ian Crozier11, Kai Dallmeier12, Leon de Waal13, Emmie de Wit14, Leen Delang12, Erik Dohm15, W Paul Duprex16, Darryl Falzarano17, Courtney L Finch18, Matthew B Frieman19, Barney S Graham20, Lisa E Gralinski8, Kate Guilfoyle13, Bart L Haagmans21, Geraldine A Hamilton22, Amy L Hartman16, Sander Herfst21, Suzanne J F Kaptein12, William B Klimstra23, Ivana Knezevic5, Philip R Krause24, Jens H Kuhn18, Roger Le Grand25, Mark G Lewis7, Wen-Chun Liu6, Pauline Maisonnasse25, Anita K McElroy26, Vincent Munster14, Nadia Oreshkova27, Angela L Rasmussen28, Joana Rocha-Pereira12, Barry Rockx21, Estefanía Rodríguez1,2, Thomas F Rogers29, Francisco J Salguero4, Michael Schotsaert6, Koert J Stittelaar13, Hendrik Jan Thibaut12, Chien-Te Tseng30, Júlia Vergara-Alert31, Martin Beer32, Trevor Brasel30, Jasper F W Chan33, Adolfo García-Sastre6, Johan Neyts12, Stanley Perlman34, Douglas S Reed23, Juergen A Richt35, Chad J Roy36, Joaquim Segalés31,37, Seshadri S Vasan38,39, Ana María Henao-Restrepo40, Dan H Barouch41.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the aetiological agent of coronavirus disease 2019 (COVID-19), an emerging respiratory infection caused by the introduction of a novel coronavirus into humans late in 2019 (first detected in Hubei province, China). As of 18 September 2020, SARS-CoV-2 has spread to 215 countries, has infected more than 30 million people and has caused more than 950,000 deaths. As humans do not have pre-existing immunity to SARS-CoV-2, there is an urgent need to develop therapeutic agents and vaccines to mitigate the current pandemic and to prevent the re-emergence of COVID-19. In February 2020, the World Health Organization (WHO) assembled an international panel to develop animal models for COVID-19 to accelerate the testing of vaccines and therapeutic agents. Here we summarize the findings to date and provides relevant information for preclinical testing of vaccine candidates and therapeutic agents for COVID-19.Entities:
Mesh：
Substances：
Year: 2020 PMID： 32967005 PMCID： PMC8136862 DOI： 10.1038/s41586-020-2787-6
Source DB: PubMed Journal: Nature ISSN： 0028-0836 Impact factor: 49.962